1st Floor, Unex House
132-134 Hills Road
Tel: 44-0-1223 341150
227 articles with Avita Medical
AVITA Medical Announces Ten RECELL® System Presentations at the American Burn Association (ABA) Annual Meeting
Presentation describing treatment of pediatric patients with RECELL System selected as “Best of the Best Abstract”
Avita Medical Announces Collaboration with COSMOTEC, an M3 Group Company, to Commercialize the RECELL® System in Japan
COSMOTEC has filed a JPMDA application for approval to market the RECELL System in Japan
Sales temporarily interrupted while closing administrative and procedural open items related to EU certificates and unrelated to product performance
AVITA Medical, a global regenerative medicine company, announced that it filed with the ASX its Appendix 4D – Half-Year Report for the six months ended 31 December 2018.
Pre-launch U.S. product sales of A$1.1 million in second quarter
AVITA Medical Announces Nine RECELL® System Abstracts Accepted for Presentation at American Burn Association (ABA) 51st Annual Meeting
RECELL System clinical benefits and cost savings featured in 26 presentations at four burn conferences in early 2019
Strong market response to the RECELL System approval in advance of U.S. launch with 36 burn centers actively reviewing the product or placing commercial orders
AVITA Medical today announced that PM360, a leading trade magazine for marketing decision makers in the pharmaceutical, biotech, medical device, and diagnostics industries, has named AVITA as one of the most innovative companies of 2018.
AVITA Medical today announced that it has received a Research and Development Tax Incentive cash rebate from the Australian Tax Office in the amount of A$1,421,000 for the year ending 30 June 2018.
AVITA Medical Announces Hiring of Full U.S. Sales Team of Experienced Burn Professionals to Support National Launch of RECELL® System
Strong market response to the RECELL System approval in advance of U.S. launch with 32 burn centers actively reviewing the product or placing commercial orders
Leading Burn Surgeons Present Positive RECELL® System Results at 31st Annual Southern Region Burn CME Conference and Northeast Region Burn Conference
Burn surgeon presents health economic model projecting burn center will save up to USD $21 million per year treating patients with the RECELL System compared to conventional treatment
FDA approval of RECELL® System for the treatment of acute thermal burns in adults
AVITA Medical Announces Commencement of Randomized Controlled Clinical Study of RECELL® System in Treatment of Children with Burn Injuries
Clinical study is being conducted in Brisbane, Australia, in collaboration with the Queensland University of Technology and Lady Cilento Children’s Hospital
Multiple U.S. burn centers incorporating RECELL System into their practices in advance of national U.S. market launch
AVITA Medical Announces Medical Education Symposium and Presentation of RECELL® System Pivotal Trial Results at U.S. Midwest Region Burn Conference
AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that a medical education symposium on the use of the RECELL® Autologous Cell Harvesting Device (RECELL® System)
AVITA Medical announced that it has received a Research and Development Tax Incentive cash rebate from the Australian Tax Office in the amount of A$1.0 million for the year ending 30 June 2017.
AVITA Medical Announces FDA Approval of the RECELL® System for the Treatment of Severe Burns in the U.S.
Point-of-care regenerative medicine technology approved to treat second- and third-degree burns using Spray-On Skin™ Cells product
AVITA Medical Announces Commencement of Manufacturing of RECELL® Device in Newly Acquired Facility in Preparation for Planned U.S. Launch
AVITA Medical today announced the successful completion of multiple production runs for the RECELL Device® within its newly acquired manufacturing facility in Ventura, California.
AVITA Medical Announces Presentation of RECELL® Device Effectiveness and Safety in Treatment of Thermal Burns at Premier U.S. Military Conference
Results from two U.S. pivotal trials featured in plenary session at U.S. Defense Department Military Health System Research Symposium
FDA approves expansion of program to include up to 108 patients and 26 U.S. burn centers